Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01622348 · ClinicalTrials.gov registry record · Phase 2
Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
A Phase 2 study, sponsored by Idera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT01622348: Completed Phase 2 study, sponsored by Idera Pharmaceuticals.
NCT01622348 is a Phase 2 study that has completed, run by Idera Pharmaceuticals. The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01622348, a Phase 2 study, has completed, sponsored by Idera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.
Primary Outcome
The change from pre-treatment baseline to End-of-Treatment (EOT) in the epidermal thickness of the index lesion
Interventions
- DRUG IMO-3100 at 0.16 mg/kg
- DRUG Saline for Injection
- DRUG IMO-3100 at 0.32 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT01622348 record still lists
NCT01622348 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 3 interventions - of which IMO-3100 at 0.16 mg/kg is the first listed.
NCT01622348 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01622348 about?
NCT01622348 is a clinical study titled "Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis". The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.
What is the current status of trial NCT01622348?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2012-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01622348?
The interventions under investigation include: IMO-3100 at 0.16 mg/kg (DRUG), Saline for Injection (DRUG), IMO-3100 at 0.32 mg/kg (DRUG).
Who is sponsoring clinical trial NCT01622348?
This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01622348's enrollment target sits among peer trials
44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia